2C-T-35

2C-T-35

Clinical data
Other names	2C-T-DFM; 4-Difluoromethylthio-2,5-dimethoxyphenethylamine
Identifiers
IUPAC name 2-[4-(difluoromethylsulfanyl)-2,5-dimethoxyphenyl]ethanamine
PubChem CID	169149411
Chemical and physical data
Formula	C11H15F2NO2S
Molar mass	263.30 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC1=CC(=C(C=C1CCN)OC)SC(F)F
InChI InChI=1S/C11H15F2NO2S/c1-15-8-6-10(17-11(12)13)9(16-2)5-7(8)3-4-14/h5-6,11H,3-4,14H2,1-2H3 Key:IMXLEUNJGUBEMC-UHFFFAOYSA-N

2C-T-35, also known as 2C-T-DFM or as 4-difluoromethylthio-2,5-dimethoxyphenethylamine, is a designer drug from the substituted phenethylamine family, which was first synthesised by Josh Hartsel and colleagues in 2024. It is a potent agonist at the serotonin receptor 5-HT_2A in vitro, with a binding affinity (K_i) of 6.3  nM. In animal studies, 2C-T-DFM was the most effective compound at producing a head-twitch response out of a series of related analogues, with an average of 33 head-twitches per 10 minutes compared to 21 for 2C-T-TFM. ^[1] While it had previously been proposed as a theoretical compound, 2C-T-35 is not known to have been tested in humans. ^[2] It is a controlled substance in Canada under phenethylamine blanket-ban language. ^[3]

See also

• 2C (psychedelics)
• 2C-T-21.5
• 2C-T-29

References

1. Varty GB, Canal CE, Mueller TA, Hartsel JA, Tyagi R, Avery K, Morgan ME, Reichelt AC, Pathare P, Stang E, Palfreyman MG, Nivorozhkin A (April 2024). "Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT₂ Receptor Agonist". Journal of Medicinal Chemistry. 67 (8): 6144–6188. doi:10.1021/acs.jmedchem.3c01961. PMID   38593423.
2. Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine Von der Struktur zur Funktion. Nachtschatten Verlag AG. pp. 792–795. ISBN   978-3-03788-700-4.
3. "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.